Reclaman mayor compromiso de las farmacéuticas

El Interfaith Center on Corporate Responsibility (ICCR) presentó un informe en el que evalúa a 15 farmacéuticas y concluye que todas están fallando en su aporte a los grandes problemas que enfrentan los países en vías de desarrollo, especialmente en HIV/Sida, malaria y tuberculosis. "Son muertes que podrían evitarse, vidas que podrían alargarse y personas que podrían salvarse, si es que elegimos salvarlas", fue una de las declaraciones más fuertes del reporte...En la categoría "accesibilidad" los autores del reporte sugieren que voluntariamente den la licencia de los genéricos a los productores de países en vías de desarrollo...GlaxoSmithKline...obtuvo los mejores puntajes. Le siguieron...Merck, Bristol-Myers Squibb y Gilead Sciences. Otra empresa que se destacó fue...Sanofi-aventis...Por el contrario, las que obtuvieron peores resultados fueron Abbott...y Boehringer...

Linha do tempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Data:

4 Mar 2014

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Data:

30 Nov 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Data:

13 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Data:

12 Set 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Data:

6 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Data:

6 Set 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Reclaman mayor compromiso de las farmacéuticas

Data:

31 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Data:

23 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Data:

17 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Data:

17 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Data:

14 Ago 2006

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Data:

1 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Data:

1 Ago 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Data:

8 Jan 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Data:

8 Jan 2006

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English

Veja a história completa

Carregar mais Ver menos

Business & Human Rights
Resource Centre

Centro de Informação sobre Empresas e Direitos Humanos

Esta página não está disponível em Português e está sendo exibida em Spanish

Reclaman mayor compromiso de las farmacéuticas

Linha do tempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.